Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphangioleiomyomatosis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 12 Neoplasms 7 Ovarian Neoplasms 6 Colorectal Neoplasms 4 Prostatic Neoplasms 3 Carcinoma, Hepatocellular 3 Uterine Cervical Neoplasms 2 Recurrence 2 Peritoneal Neoplasms 2 Lung Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Renal Cell 2 Breast Neoplasms 2 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Radiation Pneumonitis 1 Patients With Any Advanced Solid Tumors 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Mesothelioma, Malignant 1 Melanoma, Cutaneous Malignant 1 Malignant Solid Tumour 1 Lymphangioleiomyomatosis 1 Leukemia, Myeloid, Acute 1

Interventions

Sirolimus 6 Everolimus 5 saracatinib 1 nintedanib 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Letrozole 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03062943 2022-09-28

LAM

IRCCS Multimedica

Phase 2 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡